Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This study found that a lotion containing specific plant extracts significantly increased the number of anagen hairs and the anagen/telogen ratio in subjects with androgenetic alopecia after three months of use.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

This study suggests that intercellular communication via the WNT5A and STAT pathways may partly drive EMT-like phenomena in keloid pathogenesis, based on findings in an animal model.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

In this study, the researchers using Shh-GFP^+/- mice found that cyclophosphamide-induced alopecia involves the JAK/STAT1 pathway, where STAT1 binds the Shh gene promoter, decreasing Shh-expressing cells in hair follicles. Treatment with JAK inhibitors helped rescue hair loss, implicating the JAK/STAT1 pathway in this process.

This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study identified a specific subset of macrophages as a key source of oncostatin M, maintaining hair follicle stem cell quiescence during the resting phase in mice, suggesting a potential target for treating hair disorders.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

Oenocarpus bataua vegetable oil may help reduce hair loss by affecting a key gene pathway.

This study identified key genes and signaling pathways involved in the growth phases of Pashmina goat hair follicles, highlighting the role of several gene families and transcription factors in fiber quality and growth regulation.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This review describes various T-cell-mediated alopecias characterized by distinct lymphocytic patterns and explores their pathophysiology. It highlights the role of CD8+ and regulatory T cells, the JAK/STAT pathway, and stem cell niches, contributing to understanding and potentially addressing these hair loss conditions.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.